Please login to the form below

lenvatinib

This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
NICE reverses its rejection of Eisai’s Lenvima

The National Institute for Health and Care Excellence (NICE) has recommended the use of Lenvima (lenvatinib) after manufacturer Eisai was able to supply new data on its use. ... that NICE is finally recommending the use of lenvatinib so that patients
NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
NICE backs Eisai's Halaven for breast cancer

The company "would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients, however so far an unacceptable process has again
Eisai wins EU licence for kidney cancer drug Kisplyx

The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC) after an accelerated assessment. ... We remain committed to exploring the potential of lenvatinib for people with cancer, their

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager or AD - Medical Communications: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager – Med Comms – London: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Scientific Director: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Medical Writer - (London, Brighton or Copenhagen): Competitive

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Medical Writer: Great salary and benefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Programme Executive: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...